论文部分内容阅读
目的观察美多巴联合泰舒达治疗帕金森患者临床效果。方法选取医院收治的帕金森患者75例为研究对象,随机分为单药组(37例)联合用药组(38例)。单药组采用泰舒达治疗,联合用药组采用美多巴联合泰舒达治疗。观察2组治疗总有效率,治疗前后改良Webster症状量表评分、运动功能评定量表MDRSPD评分。结果联合用药组治疗总有效率为97.37%,高于单药组的81.08%(P<0.05)。2组治疗后改良Webster症状量表评分、运动功能评定量表MDRSPD评分均优于治疗前(P<0.05);联合用药组治疗后2项评分均优于单药组(P<0.05)。结论美多巴合用泰舒达治疗帕金森患者临床治疗效果确切,可有效改善患者临床症状和运动功能,药物安全性高,值得临床推广应用。
Objective To observe the clinical effect of metoparamin combined with teicastar in patients with Parkinson’s disease. Methods A total of 75 Parkinson patients admitted to hospital were selected as study subjects and randomly divided into single drug group (n = 37) and combination drug group (n = 38). The single drug group was treated with testicide, and the combined drug group was treated with metaseldal and teichoide. The total effective rate of the two groups was observed. The scores of modified Webster symptom scale and MDRSPD score before and after treatment were observed. Results The total effective rate of combination therapy group was 97.37%, higher than that of the single drug group (81.08%, P <0.05). The scores of Modified Webster Symptom Scale and MDRSPD scores of both groups were better than those before treatment (P <0.05). The scores of two groups in the combination group were better than those in the single drug group (P <0.05). Conclusion Combined treatment of teicopal and docetaxel in patients with Parkinson’s disease clinical treatment is exact, can effectively improve the clinical symptoms and motor function, high drug safety, it is worth promoting the clinical application.